Liguang Lou - Concepedia

Author

Liguang Lou

Shanghai Institute of Materia Medica ORCID

Also Known As

L G Lou, L Lou, L. Lou, LI-GUANG Lou, Li-Guang Lou, Li-guang Lou, Liguang Lou, Li‐Guang Lou, Lou Liguang, Lou, Li-Guang

323

Publications

4.9K

Citations

H-Index

Concepts

All Affiliations

Shanghai Institute of Materia Medica Chinese Academy of Sciences University of Chinese Academy of Sciences Kunming Institute of Botany Kunming Institute of Precious Metals

About

Liguang Lou is an author at Shanghai Institute of Materia Medica specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	28	49	2.1K
2	Natural Sciences	17	25	979
3	Engineering	4	4	94
4	Health Sciences	2	2	73
5	Social Sciences	1	1	84

Liguang Lou

Publications

4.4K

Citations

H-Index

Page 1

	Year	Citations
YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor‐2 tyrosine kinase with potent activity <i>in vitro</i> and <i>in vivo</i> Shu Tian, Haitian Quan, Chengying Xie, Cancer Science	2011	516
Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor Chengying Xie, Xiaozhe Wan, Haitian Quan, Cancer Science	2018	363
Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer Xin Li, Changyong Yang, Hong Wan, European Journal of Pharmaceutical Sciences Breast OncologyMedicinePharmacologyFavorable Safety ProfilesBreast Cancer	2017	218
Synthesis and biological evaluation of novel 2,4,5-substituted pyrimidine derivatives for anticancer activity Fuchun Xie, Hongbing Zhao, Lizhi Zhao, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryDerivative (Chemistry)BiochemistryMedicineNatural Sciences	2008	180
A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity Xuejing Yao, Jing Jiang, Xin Wang, Breast Cancer Research and Treatment MedicineImmunologyBiological TherapyAntibody EngineeringAnti-cancer Agent	2015	110
An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer Hongwen Li, Chao Yu, Jing Jiang, Cancer Biology & Therapy Cancer Target TherapyMedicineAntibody-drug ConjugateImmunologyPharmacology	2016	91
Pharmacologic characterization of fluzoparib, a novel poly(<scp>ADP</scp>‐ribose) polymerase inhibitor undergoing clinical trials Lei Wang, Changyong Yang, Chengying Xie, Cancer Science	2019	87
Modulation of Ca2+/calmodulin-dependent protein kinase II activity by acute and chronic morphine administration in rat hippocampus: differential regulation of alpha and beta isoforms. Liguang Lou, Tianhua Zhou, Ping Wang, PubMed Chronic Morphine AdministrationMolecular PainPharmacotherapySocial SciencesMolecular Pharmacology	1999	84
Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models Fei Long, Ye He, Haoyu Fu, Cancer Science	2019	79
cAMP Inhibition of Akt Is Mediated by Activated and Phosphorylated Rap1b Liguang Lou, Julie Urbani, Fernando Ribeiro-Neto, Journal of Biological Chemistry Molecular RegulationMolecular BiologyCell CycleCamp InhibitionCellular Physiology	2002	76

Page 1